Inhibition of α-toxin production by subinhibitory concentrations of naringenin controls Staphylococcus aureus pneumonia

Fitoterapia

Volumn 86, Issue 1, 2013, Pages 92-99

  Zhang, Yu ^a   Wang, Jian Feng ^a   Dong, Jing ^a   Wei, Jing Yuan ^b   Wang, Ya Nan ^a   Dai, Xiao Han ^a   Wang, Xin ^a   Luo, Ming Jing ^a   Tan, Wei ^a   Deng, Xu Ming ^a   Niu, Xiao Di ^a  

^a JILIN UNIVERSITY   (China)

^b Liaoning Province Academy of Analytic Science   (China)

Author keywords

Toxin; Naringenin; Pneumonia; Staphylococcus aureus

Indexed keywords

ANTIINFECTIVE AGENT; NARINGENIN; STAPHYLOCOCCUS ALPHA TOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HEMOLYSIS; HUMAN; HUMAN CELL; HYPEREMIA; LUNG ALVEOLUS EPITHELIUM; LUNG INJURY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAPHYLOCOCCAL PNEUMONIA;

ANIMALS; BACTERIAL TOXINS; CELL LINE; CITRUS PARADISI; FEMALE; FLAVANONES; HUMANS; INFLAMMATION; LYCOPERSICON ESCULENTUM; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED C57BL; PHYTOTHERAPY; PLANT EXTRACTS; PNEUMONIA, STAPHYLOCOCCAL; VIRULENCE FACTORS;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUS; STAPHYLOCOCCUS AUREUS;

EID: 84876346880     PISSN: 0367326X     EISSN: 18736971     Source Type: Journal    
DOI: 10.1016/j.fitote.2013.02.001     Document Type: Article

References (34)

1. D.M. Elston Community-acquired methicillin-resistant Staphylococcus aureus J Am Acad Dermatol 56 2007 1 16
2. C.L. Moore, A. Hingwe, S.M. Donabedian, M.B. Perri, S.L. Davis, and N.Z. Haque Comparative evaluation of epidemiology and outcomes of methicillin-resistant Staphylococcus aureus (MRSA) USA 300 infections causing community- and healthcare-associated infections Int J Antimicrob Agents 34 2009 148 155
3. H.C. Maltezou, and H. Giamarellou Community-acquired methicillin- resistant Staphylococcus aureus infections Int J Antimicrob Agents 27 2006 87 96
4. V.T. Nguyen, and Kamio Yoshiyuki Cooperative assembly of β-barrel pore-forming toxins J Biochem 136 2004 563 567
5. P.M. Schlievert, K.L. Strandberg, Y.C. Lin, M.L. Peterson, D. Pharm, and D.Y.M. Leung Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic dermatitis J Allergy Clin Immunol 125 2010 39 49
6. L. Song, M.R. Hobaugh, C. Shustak, S. Cheley, H. Bayley, and J.E. Gouaux Structure of staphylococcal alpha-hemolysin, a heptameric transmembrane pore Science 274 1996 1859 1866
7. J. Bubeck Wardenburg, and O. Schneewind Vaccine protection against Staphylococcus aureus pneumonia J Exp Med 205 2008 287 294
8. M.C. Callegan, L.S. Engel, J.M. Hill, and R.J. O'Callaghan Corneal virulence of Staphylococcus aureus: roles of alpha-toxin and proteinA in pathogenesis Infect Immun 62 1994 2478 2482
9. G. Du, L. Jin, X. Han, Z. Song, H. Zhang, and W. Liang Naringenin: a potential immunomodulator for inhibiting lung fibrosis and metastasis Cancer Res 69 2009 3205 3321
10. S. Kanno, A. Tomizawa, T. Hiura, Y. Osanai, A. Shouji, and M. Ujibe Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice Biol Pharm Bull 28 2005 527 530
11. J. Goldwasser, P.Y. Cohen, W. Lin, D. Kitsberg, P. Balaguer, and S.J. Polyak Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism J Hepatol 55 2011 963 971
12. C. Bodet, V.D. La, F. Epifano, and D. Grenier Naringenin has anti-inflammatory properties in macrophage and ex vivo human whole-blood models J Periodontal Res 43 2008 400 407
13. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing; Fifteenth informational supplement CLSI/NCCLS document M100-S15 2005 Clinical and Laboratory Standards Institute (CLSI) Wayne, PA
14. J. Qiu, J. Wang, H. Luo, X. Du, H. Li, and M. Luo The effects of subinhibitory concentrations of costus oil on virulence factor production in Staphylococcus aureus J Appl Microbiol 110 2011 333 340
15. K. Sambanthamoorthy, M.S. Smeltzer, and M.O. Elasri Identification and characterization of msa (SA1233), a gene involved in expression of SarA and several virulence factors in Staphylococcus aureus Microbiology 152 2006 2559 2572
16. D.L. Heymann Resistance to anti-infective drugs and the threat to public health Cell 124 2006 671 675
17. P. Sarkar, and I.M. Gould Antimicrobial agents are societal drugs: how should this influence prescribing? Drugs 66 2006 893 901
18. G.H. Talbot, J. Bradley, J.E. Edwards Jr., D. Gilbert, M. Scheld, and J.G. Bartlett Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America Clin Infect Dis 42 5 2006 657 668
19. S.R. Norrby, C.E. Nord, and R. Finch Lack of development of new antimicrobial drugs: a potential serious threat to public health Lancet Infect Dis 5 2005 115 119
20. B. Spellberg, J.H. Powers, E.P. Brass, L.G. Miller, and J.E. Edwards Jr. Trends in antimicrobial drug development: implications for the future Clin Infect Dis 38 2004 1279 1286
21. D.A. Rasko, and V. Sperandio Anti-virulence strategies to combat bacteria-mediated disease Nat Rev Drug Discov 9 2010 117 128
22. A.J. Bramley, A.H. Patel, M. O'Reilly, R. Foster, and T.J. Foster Roles of alpha-toxin and beta-toxin in virulence of Staphylococcus aureus for the mouse mammary gland Infect Immun 57 1989 2489 2494
23. M.C. Callegan, L.S. Engel, J.M. Hill, and R.J. O'Callaghan Corneal virulence of Staphylococcus aureus: roles of alpha-toxin and protein A in pathogenesis Infect Immun 62 1994 2478 2482
24. J. Bubeck Wardenburg, R.J. Patel, and O. Schneewind Surface proteins and exotoxins are required for the pathogenesis of Staphylococcus aureus pneumonia Infect Immun 75 2007 1040 1044
25. B.E. Ragle, V.A. Karginov, and Wardenburg J. Bubeck Prevention and treatment of Staphylococcus aureus pneumonia with a beta-cyclodextrin derivative Antimicrob Agents Chemother 54 2010 298 304
26. D.A. Rasko, C.G. Moreira, R. Li de, N.C. Reading, J.M. Ritchie, and M.K. Waldor Targeting QseC signaling and virulence for antibiotic development Science 321 2008 1078 1080
27. D.T. Hung, E.A. Shakhnovich, E. Pierson, and J.J. Mekalanos Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization Science 310 2005 670 674
28. T.M. Jarry, G. Memmi, and A.L. Cheung The expression of alpha-haemolysin is required for Staphylococcus aureus phagosomal escape after internalization in CFT-1 cells Cell Microbiol 10 9 2008 1801 1814
29. R.P. Novick Autoinduction and signal transduction in the regulation of staphylococcal virulence Mol Microbiol 48 6 2003 1429 1449
30. A. Abdelnour, S. Arvidson, T. Bremell, C. Rydén, and A. Tarkowski The accessory gene regulator (agr) controls Staphylococcus aureus virulence in a murine arthritis model Infect Immun 61 9 1993 3879 3885
31. R.R. Ortiz-Andrade, J.C. Sánchez-Salgado, G. Navarrete- Vázquez, S.P. Webster, M. Binnie, and S. García-Jiménez Antidiabetic and toxicological evaluations of naringenin in normoglycaemic and NIDDM rat models and its implications on extra-pancreatic glucose regulation Diabetes Obes Metab 10 11 2008 1097 1104
32. M. Shulman, M. Cohen, A. Soto-Gutierrez, H. Yagi, H. Wang, and J. Goldwasser Enhancement of naringenin bioavailability by complexation with hydroxypropoyl-β-cyclodextrin PLoS One 6 4 2011 e18033
33. M. Paul, and L. Leibovici Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses Infect Dis Clin North Am 23 2009 277 293
34. L. Cegelski, G.R. Marshall, G.R. Eldridge, and S.J. Hultgren The biology and future prospects of antivirulence therapies Nat Rev Microbiol 6 2008 17 27